Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
03:41pm, Thursday, 18'th Jun 2026
Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, via partnership with GSK. SPRO stands to receive milestone
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
10:55am, Thursday, 18'th Jun 2026
BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
10:01am, Thursday, 18'th Jun 2026
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
12:36pm, Wednesday, 17'th Jun 2026
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Uteb
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
11:11am, Wednesday, 17'th Jun 2026
The U.S. FDA has approved GSK's oral antibiotic to treat complicated urinary tract infections, the regulator said on Wednesday, giving patients a new treatment option
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
03:21pm, Tuesday, 16'th Jun 2026
Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder
10:56am, Friday, 12'th Jun 2026
GSK's momelotinib wins FDA and EMA orphan status for VEXAS syndrome, backed by early evidence. The company advances a phase II/III study.
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvalued
06:04pm, Thursday, 11'th Jun 2026
On June 11, 2026, GSK PLC (GSK) shares rose 3.3% to a current price of $52.86. The stock has shown strong momentum over the past year, with a 31.8% increase, an
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
02:26pm, Thursday, 11'th Jun 2026
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
12:27pm, Thursday, 11'th Jun 2026
The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
02:04am, Thursday, 11'th Jun 2026
GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZen
GSK plc (GSK) M&A Call Transcript
03:52pm, Wednesday, 10'th Jun 2026
GSK plc (GSK) M&A Call Transcript
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
11:19am, Wednesday, 10'th Jun 2026
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of N
GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
08:42am, Wednesday, 10'th Jun 2026
GSK PLC's (LSE:GSK, NYSE:GSK) $10.6 billion (£8bn) acquisition of US biotech Nuvalent has achieved something unusual in large pharmaceutical M&A: analysts broadly agree it makes sense. The debate i
Thistle Resources intersects broad gold mineralization at Middle River
06:01am, Wednesday, 10'th Jun 2026
Thistle Resources (TSX-V:TRCG, OTC:TRCGF) has intersected broad, high-grade gold mineralization at its Middle River Gold Project, the company said...
